BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004. [PMID: 17075118 DOI: 10.1200/JCO.2006.06.8809] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Huang W, Su D, Liao X, Yang T, Lu Y, Zhang Z. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer. Sci Rep 2023;13:789. [PMID: 36646765 DOI: 10.1038/s41598-023-27826-7] [Reference Citation Analysis]
2 Liang J, Feng Y, Liu Y, Shi K, Zhou G, Liu L, Liu Y, Qiao K, Liu W, Wang X. Serum soluble DR5 predicts mortality risk in patients with HBV-related hepatocellular carcinoma. Front Oncol 2022;12:1040812. [PMID: 36605430 DOI: 10.3389/fonc.2022.1040812] [Reference Citation Analysis]
3 Zhang S, Chen Z, Shi P, Fan S, He Y, Wang Q, Li Y, Ramalingam SS, Owonikoko TK, Sun SY. Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. Theranostics 2021;11:3964-80. [PMID: 33664875 DOI: 10.7150/thno.54824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Fan X, Li Y, Yi X, Chen G, Jin S, Dai Y, Cui B, Dai B, Lin H, Zhou D. Epigenome-wide DNA methylation profiling of portal vein tumor thrombosis (PVTT) tissues in hepatocellular carcinoma patients. Neoplasia 2020;22:630-43. [PMID: 33059309 DOI: 10.1016/j.neo.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wan Z, Zhang X, Yu X, Hou Y. Prognostic significance of serum soluble DR5 levels in small-cell lung cancer. Int J Med Sci 2019;16:403-8. [PMID: 30911274 DOI: 10.7150/ijms.28814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kim SW, Moon JH, Park SY. Activation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors. Oncotarget 2016;7:65660-8. [PMID: 27582540 DOI: 10.18632/oncotarget.11597] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
7 Kim SW, Moon JH, Park SY. Activation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors. Oncotarget. 2016;7:65660-65668. [PMID: 27582540 DOI: 10.18632/oncotarget.115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang W, Li J, Wen Q, Luo J, Chu S, Chen L, Qing Z, Xie G, Xu L, Alnemah MM, Li M, Fan S, Zhang H. 4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation. Oncotarget 2016;7:21728-41. [PMID: 26942880 DOI: 10.18632/oncotarget.7824] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
9 Krainer M, El-gazzar A. DR4 and DR5. Cancer Therapeutic Targets 2017. [DOI: 10.1007/978-1-4419-0717-2_9] [Reference Citation Analysis]
10 Danish L, Stöhr D, Scheurich P, Pollak N. TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer. Resistance to Targeted Anti-Cancer Therapeutics 2017. [DOI: 10.1007/978-3-319-56805-8_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Kim SW, Lee JH, Moon JH, Nazim UM, Lee YJ, Seol JW, Hur J, Eo SK, Lee JH, Park SY. Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation. Oncotarget 2016;7:4356-68. [PMID: 26517672 DOI: 10.18632/oncotarget.5374] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
12 Tanenbaum DG, Hall WA, Colbert LE, Bastien AJ, Brat DJ, Kong J, Kim S, Dwivedi B, Kowalski J, Landry JC, Yu DS. TNFRSF10C copy number variation is associated with metastatic colorectal cancer. J Gastrointest Oncol 2016;7:306-14. [PMID: 27284460 DOI: 10.21037/jgo.2015.11.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
13 Makoukji J, Raad M, Genadry K, El-Sitt S, Makhoul NJ, Saad Aldin E, Nohra E, Jabbour M, Sangaralingam A, Chelala C, Habib RH, Boulos F, Tfayli A, Boustany RM. Association between CLN3 (Neuronal Ceroid Lipofuscinosis, CLN3 Type) Gene Expression and Clinical Characteristics of Breast Cancer Patients. Front Oncol 2015;5:215. [PMID: 26528430 DOI: 10.3389/fonc.2015.00215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hernandez-Cueto A, Hernandez-Cueto D, Antonio-Andres G, Mendoza-Marin M, Jimenez-Gutierrez C, Sandoval-Mejia AL, Mora-Campos R, Gonzalez-Bonilla C, Vega MI, Bonavida B, Huerta-Yepez S. Death receptor 5 expression is inversely correlated with prostate cancer progression. Mol Med Rep 2014;10:2279-86. [PMID: 25174820 DOI: 10.3892/mmr.2014.2504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
15 Johnston PG. Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. Oncologist 2014;19:568-73. [PMID: 24718513 DOI: 10.1634/theoncologist.2014-038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
16 Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013;169:1723-44. [PMID: 23638798 DOI: 10.1111/bph.12238] [Cited by in Crossref: 135] [Cited by in F6Publishing: 146] [Article Influence: 15.0] [Reference Citation Analysis]
17 Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ, Kuppen PJ. The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer 2013;5:13-29. [PMID: 24179395 DOI: 10.4137/BIC.S11475] [Cited by in Crossref: 46] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
18 Krainer M, El-gazzar A. DR4 and DR5. Cancer Therapeutic Targets 2013. [DOI: 10.1007/978-1-4614-6613-0_9-2] [Reference Citation Analysis]
19 Kriegl L, Jung A, Horst D, Rizzani A, Jackstadt R, Hermeking H, Gallmeier E, Gerbes AL, Kirchner T, Göke B, De Toni EN. Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PLoS One 2012;7:e51654. [PMID: 23284732 DOI: 10.1371/journal.pone.0051654] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 2012;12:58. [PMID: 22313795 DOI: 10.1186/1471-2407-12-58] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
21 Kuratnik A, Senapati VE, Verma R, Mellone BG, Vella AT, Giardina C. Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest. Biochem Pharmacol 2012;83:1217-28. [PMID: 22306067 DOI: 10.1016/j.bcp.2012.01.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
22 Belov L, Zhou J, Christopherson RI. Cell surface markers in colorectal cancer prognosis. Int J Mol Sci 2010;12:78-113. [PMID: 21339979 DOI: 10.3390/ijms12010078] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
23 Elrod HA, Fan S, Muller S, Chen GZ, Pan L, Tighiouart M, Shin DM, Khuri FR, Sun SY. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One 2010;5:e12178. [PMID: 20808443 DOI: 10.1371/journal.pone.0012178] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
24 Bavi P, Prabhakaran SE, Abubaker J, Qadri Z, George T, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Uddin S, Al-Kuraya KS. Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer 2010;9:203. [PMID: 20673328 DOI: 10.1186/1476-4598-9-203] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
25 McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010;16:3442-51. [PMID: 20570920 DOI: 10.1158/1078-0432.CCR-10-0052] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
26 Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, Raats DA, Sprick MR, Schaefer U, Van Houdt WJ, De Bruijn MT, Schackmann RC, Derksen PW, Medema JP, Walczak H, Borel Rinkes IH, Kranenburg O. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010;138:2357-67. [PMID: 20188103 DOI: 10.1053/j.gastro.2010.02.046] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 8.6] [Reference Citation Analysis]
27 Masuoka HC, Sinicrope FA. Clinical Relevance of Apoptotic Regulatory Proteins in Colorectal Cancers. Curr Colorectal Cancer Rep 2010;6:111-7. [DOI: 10.1007/s11888-010-0051-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Koornstra JJ, de Jong S, Boersma-van Eck W, Zwart N, Hollema H, de Vries EG, Kleibeuker JH. Fas ligand expression in lynch syndrome-associated colorectal tumours. Pathol Oncol Res 2009;15:399-406. [PMID: 19067240 DOI: 10.1007/s12253-008-9136-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
29 Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V, Coskun U, Yamac D, Sancak B, Uner A. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol 2010;136:1471-6. [PMID: 20155284 DOI: 10.1007/s00432-010-0803-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
30 Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res 2008;68:8312-21. [PMID: 18922903 DOI: 10.1158/0008-5472.CAN-07-6736] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
31 Corcoran CA, He Q, Ponnusamy S, Ogretmen B, Huang Y, Sheikh MS. Neutral sphingomyelinase-3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies. Mol Cancer Res 2008;6:795-807. [PMID: 18505924 DOI: 10.1158/1541-7786.MCR-07-2097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
32 Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 2008;14:2180-9. [PMID: 18381960 DOI: 10.1158/1078-0432.CCR-07-1392] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
33 Wilson TR, Longley DB, Johnston PG. Therapeutic Targeting of Apoptosis in Cancer. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy 2008. [DOI: 10.1007/978-1-59745-474-2_16] [Reference Citation Analysis]
34 Compton C, Hawk E, Grochow L, Lee F, Ritter M, Niederhuber JE. Colon Cancer. Abeloff's Clinical Oncology 2008. [DOI: 10.1016/b978-0-443-06694-8.50085-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]